Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$10.33 USD
+0.09 (0.88%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $10.45 +0.12 (1.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADPT 10.33 +0.09(0.88%)
Will ADPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Other News for ADPT
COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake
Adaptive Biotechnologies price target raised by $2 at BTIG, here's why
BTIG Increases Price Target for Adaptive Biotechnologies (ADPT) to $13
Aristotle Large Cap Growth Q2 2025 Commentary
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics